Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Nova Ltd (NVMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Nova Ltd — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Nova Ltd trades at $325.62 (market cap $10.89B). The key difference: Nova Ltd is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Nova Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Nova Ltd for 6 Days on average.
| HNGE | NVMI | |
|---|---|---|
Market Cap | $8.48B | $10.89B |
Volume | 879,799 | 416,153 |
Sector | Health | Technology |
52-Week High | $105.14 | $605.65 |
52-Week Low | $31.17 | $275.78 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.10B | $10.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
NVMI trades at $342.37, up 0.58% on the day, with a bearish technical signal driven by moving averages but supported by strong fundamentals including a 28.84% net income margin and three consecutive quarterly earnings beats. The stock is positioned near its pivot point of $344, with immediate support at $336. Revenue growth is projected to increase from $881 million in 2025 to $937 million in 2026, though net cash flow turned negative in 2026.
The outlook remains positive given the 85.7% analyst buy rating and a consensus price target of $556.50, implying significant upside. Key risks include high valuation multiples like a P/E of 42.64 and negative cash flow trends, but the company's tool-of-record status in AI chip packaging provides a durable growth catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Nova Ltd
Nova provides metrology solutions for semiconductor manufacturing. Its systems measure material and process characteristics to help chipmakers control production across advanced nodes and packaging.
Read more on NVMI →
